Full Text View
Tabular View
No Study Results Posted
Related Studies
T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients
This study has been terminated.
Study NCT00057382   Information provided by Tularik
First Received: March 31, 2003   Last Updated: June 23, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hepatocellular Carcinoma
Additional conditions recognized in this trial
Carcinoma
Carcinoma, Hepatocellular
More general conditions related to this trial
Adenocarcinoma
Digestive System Diseases
Digestive System Neoplasms
Liver Diseases
Liver Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Interventions listed in this trial
T138067 intravenous
doxorubicin intravenous
Additional drug interventions recognized in this trial
Doxorubicin
More general drug interventions related to this trial
Antibiotics, Antineoplastic
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Tularik


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services